Truist Resumes Coverage on PTC Therapeutics (PTCT) with Hold, Citing Growth Concerns

gurufocus.com · 2026-10-16

On October 16, 2026, Truist analyst Joon Lee resumed coverage of PTC Therapeutics Inc (NASDAQ: PTCT) with a Hold rating and a price target of $62. The firm expr

TickrTrends take: PTC Therapeutics operates in the Technology sector and is currently assessed as undervalued according to TickrTrends. The Truist analyst resumption of coverage with a Hold rating and growth concerns presents a tension worth monitoring, as the market may be pricing in slower expansion than the company's valuation suggests. Investors focused on valuation metrics should track whether PTC's fundamentals deteriorate to justify the cautious outlook or whether near-term concerns mask longer-term value creation.

Read the full story at gurufocus.com →